Yazar "Aydın, Esra" için listeleme
-
The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients
Ak, Nazmiye; Tuz, Zeynep; Aydın, Esra; Ferhatoğlu, Ferhat; Sarı, Murat; Paksoy, Nail; Doğan, İzzet; Yıldız, Anıl; Dişçi, Rian; Saip, Pınar Mualla (Scientific and Technical Research Council of Turkey, 2024)Background/aim: The study is aimed to determine the relationship between the delivery and breastfeeding history of the patients and the clinicopathological properties of breast cancer. Materials and methods: A questionnaire ... -
Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas
Okcu, Oğuzhan; Öztürk, Çiğdem; Yalçın, Nazlıcan; Yalçın, Anıl Can; Şen, Bayram; Aydın, Esra; Öztürk, Ahmet Emin (Elsevier, 2024)Introduction: Despite screening, the incidence of breast cancer is increasing worldwide. Neoadjuvant chemotherapy (NAC) response is one of the most important parameters taken into consideration in surgery, optimal adjuvant ... -
Factors affecting mortality in COVID-19 patients treated with intravenous immunoglobulin
İlkkılıç, Kadir; Cüre, Osman; Beyazal Polat, Hatice; Sen, Bayram; Aydın, Esra; Avcı, Uğur; Tüfekçi, Damla (İnönü Üniversitesi Tıp Fakültesi, 2023)Aim: Intravenous immunoglobulin (IVIG), used as an option in the treatment of severe Coronavirus disease 2019 (COVID-19), has been shown to have effects on the suppression of the hyperinflammatory state through immunomodulatory ... -
Factors affecting mortality in COVID-19 patients treated with tocilizumab
Cüre, Osman; İlkkılıç, Kadir; Şen, Bayram; Arpa, Medeni; Aydın, Esra; Avcı, Uğur; Tüfekçi, Damla; Polat, Hatice Beyazal; Kızılkaya, Bayram (Yuzuncu Yil Universitesi Tip Fakultesi, 2024)The aim of our study was to evaluate the risk factors associated with mortality in COVID-19 patients. During March 2020 to March 2022, 136 patients who were treated with tocilizumab in the service and intensive care unit ... -
The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer
Şen, Gülin Alkan; Aydın, Esra; Guliyev, Murad; Öztaş, Nihan Şentürk; Değerli, Ezgi; Demirci, Nebi Serkan; Turna, Zeynep Hande; Demirelli, Fuat Hulisi (BMC, 2024)BackgroundThe HER-2 status of breast cancer (BC) has been classified as negative or positive for a long time. Given the efficacy of novel anti-HER2-targeted antibody drug conjugates (ADCs) in HER2-low BC, a distinct subgroup ... -
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Özyurt, Neslihan; Alkan, Ali; Gülbağcı, Burcu; Seyyar, Mustafa; Aydın, Esra; Şahbazlar, Mustafa; Türker, Mehmet; Kınıkoğlu, Oğuzcan; Yerlikaya, Tahir; Dinç, Gülhan; Aytaç, Ali; Kalkan, Ziya; Ebinç, Senar; Gültürk, İlkay; Keskinkılıç, Merve; İşleyen, Zehra Sucuoğlu; Çağlayan, Dilek; Türkel, Alper; Şakalar, Teoman; Sekmek, Serhat; Yıldırım, Nilgün; Koçak, Sinem; Okutur, Kerem; Özveren, Ahmet; Dursun, Bengü; Kitaplı, Sait; Eren, Orhan Önder; Beypınar, İsmail; Hacıbekiroğlu, İlhan; Çabuk, Devrim; Karaman, Elanur; Acar, Ömer; Paydaş, Semra; Eryılmaz, Melek Karakurt; Demir, Bilgin; Oruç, Zeynep; Yılmaz, Mesut; Biricik, Fatih Selçuk; Salim, Derya Kıvrak; Tanrıverdi, Özgür; Doğan, Mutlu (Nature Research, 2024)The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Demirel, Burçin Çakan; Acar, Ömer; Aksoy, Sercan; Baytemur, Nazife Köse; Şahin, Elif; Çabuk, Devrim; Başaran, Gül; Paydaş, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Gülbağcı, Mutlu; Paksoy, Nail; Davarcı, Sena Ece; Yılmaz, Funda; Doğan, Özlem; Orhan, Sibel Oyucu; Kayıkcıoğlu, Erkan; Aytaç, Ali; Keskinkılıç, Merve; Moçan, Eda Eylemer; Ünal, Ölçün Ümit; Aydın,Esra; Yücel, Hakan; Işık, Deniz; Eren, Önder; Uluç, Başak Oyan; Özçelik, Melike; Hacıbekiroğlu, İlhan; Aydıner, Adnan; Demir, Hacer; Öksüzoğlu, Berna; Çılbır, Ebru; Çubukçu, Erdem; Çetin, Bülent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yıldırım, Nilgün; Alkan, Ali; Selçukbiricik, Fatih; Aksoy, Asude; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tuğba; Aykan, Musa Barış; İnal, Ali; İriağaç, Yakup; Kalkan, Nurhan Önal; Keser, Murat; Sakalar, Teoman; Menekşe, Serkan; Kut, Engin; Bilgin, Burak; Karaoğlanoğlu, Müge; Sunar, Veli; Özdemir, Özlem; Turhal, Nazım Serdar; Karadurmuş, Nuri; Yalçın, Bülent; Şendur, Mehmet Ali Nahit (Future Medicine Ltd, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...
